Form 10-Q · Quarterly report
Carvana 10-Q, filed Jul 29, 2026
- Filed
- CIK
- 0001690820
- Accession no.
- 0001690820-26-000055
Summary
Carvana reported that its second-quarter 2026 retail vehicle unit sales rose 37.7% year over year to 197,325 and its first-half retail unit sales rose 38.8% to 384,718, with second-quarter retail vehicle sales of $5.5 billion versus $3.4 billion a year earlier. The company also said it offered over 77,000 total website units for sale as of June 30, 2026, and estimated that 75% of the U.S. population lived within 100 miles of an inspection and reconditioning center or auction site.
Key points
- Carvana's three-month retail vehicle unit sales increased 37.7% to 197,325 for the quarter ended June 30, 2026, from 143,280 a year earlier.
- Its six-month retail vehicle unit sales increased 38.8% to 384,718, from 277,178 a year earlier.
- Retail vehicle sales totaled $5.5 billion in the second quarter of 2026 and $10.3 billion in the first half, compared with $3.4 billion and $6.4 billion in the prior-year periods.
- As of June 30, 2026, Carvana offered over 77,000 total website units and estimated that 75% of the U.S. population was within 100 miles of an inspection and reconditioning center or auction site.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT'S DISCUSSION Overview Carvana is the leading e-commerce platform for buying and selling used cars. We are transforming the used car buying and selling experience by giving consumers what they want - a wide selection, great value and quality, transparent pricing, and a simple, no pressure transaction. Our differentiated business model combines a comprehensive online sales experience with a vertically integrated supply chain, designed to sell high-quality vehicles to our customers transparently and efficiently at a low price. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.